# Safety and Efficacy Study Using ABT-335 (Investigational Drug) in Combination With Atorvastatin, to Study the Effects on Thickening of the Blood Vessel Wall in Patients With Abnormal Lipid (Fat) Levels in the Blood

> **NCT00616772** · PHASE3 · COMPLETED · sponsor: **AbbVie (prior sponsor, Abbott)** · enrollment: 682 (actual)

## Conditions studied

- Coronary Artery Disease
- Coronary Heart Disease
- Dyslipidemia

## Interventions

- **DRUG:** ABT-335
- **DRUG:** Placebo
- **OTHER:** Atorvastatin

## Key facts

- **NCT ID:** NCT00616772
- **Lead sponsor:** AbbVie (prior sponsor, Abbott)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02
- **Primary completion:** 2012-09
- **Final completion:** 2012-09
- **Target enrollment:** 682 (ACTUAL)
- **Last updated:** 2018-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00616772

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00616772, "Safety and Efficacy Study Using ABT-335 (Investigational Drug) in Combination With Atorvastatin, to Study the Effects on Thickening of the Blood Vessel Wall in Patients With Abnormal Lipid (Fat) Levels in the Blood". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00616772. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*